Opiates as potential cofactors in progression of HIV-1 infections to AIDS

Journal of Neuroimmunology

Volumn 83, Issue 1-2, 1998, Pages 77-87

  Donahoe, Robert M ^a   Vlahov, David ^b  

^a Lab Psychoimmunology Dept P   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

AIDS; Epidemiology; HIV 1; Immunology; Opiates

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; MORPHINE; OPIATE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INTRAVENOUS DRUG ABUSE; LYMPHOCYTE COUNT; MONKEY; NONHUMAN; OPIATE ADDICTION; PRIORITY JOURNAL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; HIV-1; HUMANS; NEUROIMMUNOMODULATION; OPIOID-RELATED DISORDERS;

EID: 0032520696     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(97)00224-5     Document Type: Article

References (111)

1. Alcabes P., Munoz A., Vlahov D., Friedland G.H. Incubation period of human immunodeficiency virus. Epidemiol. Rev. 15:1993;303-318.
2. Alcabes P., Schoenbaum E.E., Klein R.S. CD4+ lymphocyte level and rate of decline as predictors of AIDS in intravenous drug users with HIV infection. AIDS. 7:1993;513-517.
3. Alkhatib G., Combadiere C., Border C.C., Feng Y., Kennedy P.E., Murphy P.M., Berger E.A. CC CKR5: A RANTES, MIP1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV1. Science. 272:1996;1955-1958.
4. Andrieu J.-M., Lu W. Viro-immunopathogenesis of HIV disease: implications for therapy. Immunol. Today. 16:1995;5-7.
5. Andrieu J.-M., Lu W., Levy R. Sustained increases in CD4 cell counts in asymptomatic human immunodeficiency virus type 1-seropositive patients treated with prednisolone for 1 year. J. Infect. Dis. 171:1995;523-530.
6. Aron D.C. Endocrine complications of the acquired immunodeficiency syndrome. Arch. Intern. Med. 149:1989;330-333.
7. Arora P.K., Fride E., Petitto J., Waggie K., Skolnick P. Morphine-induced immune alterations in vivo. Cell. Immunol. 126:1990;343-353.
8. Baddley J.W., Paul D., Carr D.J.J. Acute morphine administration alters the expression of β-adrenergic receptors on splenic lymphocytes. Adv. Biosci. 86:1993;593-597.
9. Balter M. Cytokines move from the margins to the spotlight. Science. 268:1995;205-206.
10. Bryant H.U., Bernton E.W., Holaday J.W. Morphine pellet-induced immunomodulation in mice: Temporal relationships. J. Pharmacol. Exp. Ther. 245:1988;913-920.
11. Bryant H.U., Brenton E.W., Kenner J.R., Holaday J.W. Role of adrenal cortical activation in the immunosuppressive effects of chronic morphine treatment. Endocrinology. 128:1991;3253-3258.
12. Carr D.J.J., Gebhardt B.M., Paul D. Alpha adrenergic and mu-2 opioid receptors are involved in morphine-induced suppression of splenocyte natural killer activity. J. Pharmacol. Exp. Ther. 264:1993;1179-1186.
13. Chaisson R.E., Taylor E., Margolick J.B., Munoz A., Solomon L., Cohn S., Nelson K.E., Vlahov D. Immune serum markers and CD4 cell counts in HIV-infected intravenous drug users. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 5:1992;456-460.
14. Chaisson R.E., Keruly J.C., Moore R.D. Race sex, drug abuse, and progression of human immunodeficiency virus disease. New Engl. J. Med. 333:1995;751-756.
15. Chuang R.Y., Blackbourn D.J., Chuang L.F., Liu Y., Kilam K.F. Jr. Modulation of simian AIDS by opioids. Adv. Biosci. 86:1993;573-583.
16. H2 switch is a critical step in the etiology of HIV infection. Immunol. Today. 14:1993;107-111.
17. Clerici M., Bevilacqua M., Vago T., Villa M.L., Shearer G.M., Norbiato G. An immunoendocrinological hypothesis of HIV infection. Lancet. 343:1994;1552-1553.
18. Clerici M., Balotta C., Galli M. Soluble HIV suppressive factors: more than one holy grail? Immunol. Today. 17:1996;297-298.
19. Concha M., Selnes O.A., Vlahov D., Nance-Sproson T., Updike M., Royal W., Palenecik J., McCarthur J.C. Comparison of neuropsychological test performance between AIDS-free injection drug users and homosexual men. Neuroepidemiology. 16:1997;78-85.
20. Crum R.M., Galai N., Cohn S., Celentano D.D., Vlahov D. Alcohol use and T-lymphocyte subsets among injection drug users with HIV-1 infection: A prospective analysis. Alcohol Clin. Exp. Res. 20:1996;364-371.
21. Dafny N. Interferon modifies morphine withdrawal phenomenon in rodents. Neuropharmacology. 22:1983;647-651.
22. Dalgleish A.G., Beverley P.C., Clapham P.R., Crawford D.H., Greaves M.F., Weiss R.A. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature. 312:1984;763-767.
23. Daniel M.D., Letvin N.L., King N.W., Kannagi M., Sehgal P.K., Hunt R.D., Kanki P.J., Essex M., Desrosiers R.C. Isolation of T-cell tropic HTLV-III-like retrovirus from macaques. Science. 228:1985;1201-1204.
24. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study, Dean M., Carrington M., Winkler C., Huttley G.A., Smith M.W., Allikmets R., Goedert J.J., Buchbinder S.P., Vittinghoff E., Gomperts E., Donfield S., Vlahov D., Kaslow R., Saah A., Rinaldo C., Detels R., O'Brien S.J. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science. 273:1996;1856-1862.
25. DesJarlais D.C., Friedman S.R., Marmor M., Cohen H., Mildvan D., Yancovitz S., Mathur U., El-Saddr W., Spira T.J., Garber J., Beatrice S.T., Abdul-Quader A.S., Sotheran J.L. Development of AIDS, HIV seroconversion and potential cofactors for T4 cell loss in a cohort of intravenous drug users. AIDS. 1:1987;105-111.
26. Donahoe R.M. Neuroimmunomodulation by opiates: relationship to HIV-1 infection and AIDS. Adv. Neuroimmunol. 3:1993;31-46.
27. Donahoe R.M., Madden J.J., Hollingsworth F., Shafer D.A., Falek A. Morphine depression of T cell E-rosetting: Definition of the process. Fed. Proc., Fed. Am. Soc. Exp. Biol. 44:1985;95-99.
28. Donahoe R.M., Nicholson J.K.A., Madden J.J., Donahoe F., Shafer D.A., Gordon D., Bokos P., Falek A. Coordinate and independent effects of heroin, cocaine and alcohol abuse on T-cell E-rosette and antigenic marker expression. Clin. Immunol. Immunopathol. 41:1986;254-264.
29. Donahoe R.M., Bueso-Ramos C., Donahoe F., Madden J.J., Falek A. Mechanistic implications of the findings that opiates and other drugs of abuse moderate T-cell surface receptors and antigenic markers. Ann. N.Y. Acad. Sci. 496:1987;711-721.
30. Donahoe R.M., Byrd L., McClure H.M., Fultz P., Brantley M., Marsteller F., Ansari A.A., Wenzel D., Aceto M. Consequences of opiate-dependency in a monkey model of AIDS. Adv. Exp. Med. Biol. 335:1993;21-28.
31. Donahoe, R.M., Byrd, L.D., McClure, H.M., Brantley, M., Wenzel, D., Ansari, A.A., Marsteller, F., 1997. Immunological effects of opiate exposure in rhesus monkeys, with emphasis on T cell trafficking effects. Brain Behav. Immunity, (submitted).
32. Dorrucci M., Pezzotti P., Phillips A.N., Lepri C.A., Rezza G. Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. J. Infect. Dis. 172:1995;1503-1508.
33. Farzadegan H, Levy, D, Astemborski, Saah, A.J., Vlahov, D., Margolick, J.B., Graham, N.M.H., 1996. Effect of gender, race, injecting drug use and disease stage on infectious viral load among IDUs and gay men. Abstract: XI International Conference on AIDS, Vancouver, Canada.
34. Fauci A.S., Panteleo G., Stanley S., Weissman D. Immunopathogenic mechanisms of HIV infection. Ann. Intern. Med. 124:1996;654-663.
35. Fecho A., Dykstra L.A., Lysle D.T. Evidence for beta adrenergic receptor involvement in the immunomodulatory effects of morphine. J. Pharmacol. Exp. Ther. 365:1993;1079-1087.
36. Feng Y., Broder C.C., Kennedy P.E., Berger E.A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, protein-coupled receptor. Science. 272:1996;809-810.
37. Friedman, H., Klein, T.W., Spector, S., 1993. Drugs of Abuse, Immunity and AIDS. Plenum Press, New York, N.Y.
38. Friedman L.N., Williams M.T., Singh T.P., Friedan T.R. Tuberculosis, AIDS, and death among substance abusers on welfare in New York City. New Engl. J. Med. 334:1996;828-833.
39. Fuchs B.A., Pruett S. Morphine induces apoptosis in murine thymocytes in vivo but not in vitro: Involvement of both opiate and glucocorticoid receptors. J. Pharmacol. Exp. Ther. 266:1993;417-423.
40. Fultz P.N., McClure H.M., Anderson D.C., Swenson R.B., Anand R., Srinivasan A. Isolation of a T-lymphotropic retrovirus from naturally infected sooty mangabey monkeys (Cercocebus atys). Proc. Natl. Acad. Sci. U.S.A. 83:1986;5286-5290.
41. Galai, N., Taylor, E., Cohn, S., Vlahov, D., 1993. Longitudinal study of immune activation markers among injection drug users using HIV-1 seroconverters. Abstract: IX International Conference on AIDS, Berlin, Germany.
42. Galai N., Vlahov D., Margolick J.B., Chen K., Graham N.M.H., Munoz A. Changes in markers of disease progression in HIV-1 seroconverters: A comparison between cohorts of injecting drug users and homosexual men. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 8:1995;66-74.
43. Guan L., Townsend R., Eisenstein T.K., Adler M.W., Rogers T.J. Both T cells and macrophages are targets of kappa-opioid-induced immunosuppression. Brain Behav. Immun. 8:1994;229-240.
44. Heath S.L., Tew J.G., Tew J.G., Szakal A.K., Burton G.F. Follicular dendritic cells and human immunodeficiency virus infectivity. Nature. 377:1995;740-744.
45. Heijnen C.J., Kavelaars A., Ballieux R.E. Beta-endorphin: cytokine and neuropeptide. Immunol. Rev. 119:1991;41-63.
46. Hernandez M.C., Flores L.R., Bayer B.M. Immunosuppression by morphine is mediated by central pathways. J. Pharmacol. Exp. Ther. 267:1993;1336-1341.
47. Hershow R.C., Galai N., Fukuda K., Graber J., Vlahov D., Rezza G., Klein R.S., Des Jarlais D.C., Vitek C., Khabbaz R., Freels S., Zuckerman R., Pezzotti P., Kaplan J.E. An international collaborative study of the effects of coinfection with HTLV-II on HIV-1 disease progression in injection drug users. J. Infect. Dis. 174:1996;309-317.
48. Hogervorst E., Jurriaans S., de Wolf F., van Wijk A., Wiersma A., Valk M., Roos M., van Gemen B., Coutinho R., Miedema F.et al. Predictors for non- and slow progressors in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels. J. Infect. Dis. 171:1995;811-821.
49. Jason J., Lui K.Y., Rangi M.V., Hessol N.A., Darrow W.W. Risk of developing AIDS in HIV-infected cohorts of hemophiliacs and homosexual men. J. Am. Med. Assoc. 262:1989;3129-3130.
50. Kaslow R.A., Blackwelder C.W., Ostrow D.G., Yerg D., Palenicek J., Coulson A.H., Valdiserri R.O. No evidence for a role of alcohol or other psychoactive drugs in accelerating immunodeficiency in HIV-1-positive individuals. J. Am. Med. Assoc. 261:1989;3424-3429.
51. Kaslow R.A., Carrington M., Apple R., Park L., Munoz A., Saah A.J., Goedert J.J., Winkler C., O'Brien S.J., Rinaldo C., Detels R., Blattner W., Phair J., Erlich H., Mann D.L. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nature Med. 2:1996;405-411.
52. Klatzman D., Champagne E., Chamaret S., Gruest J., Guetard D., Hercend T., Gluckman J.C., Montagnier L. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature. 312:1984;767-768.
53. Kroner B.L., Goedert J.J., Carrington M., Mann D.L., Blattner W.A. Concordance of haplotype sharing, CD4 decline and AIDS in hemophilic sibling pairs. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 9:1995;275-280.
54. Kumar M., Morgan R., Szapocznik J., Eisdorfer C. Norepinephrine response in early HIV infection. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 4:1991;782-786.
55. Kumar M., Kumar A.M., Morgan R., Szapocznik J., Eisdorfer C. Abnormal pituitary-adrenocortical response in early HIV-1 infection. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 4:1993;61-65.
56. Le Goaster J., Rougeot C., Tekaia F., Dormont D., Boileau G., Montagnier L., Le Magnen J. ACTH/β-endorphins and ACTH/cortisol ratios as early markers in HIV infection. J. Environ. Pathol. Toxicol. Oncol. 10:1990;322-325.
57. Levy J.A. Changing concepts in HIV infection: challenges for the 1990s. AIDS. 4:1990;1051-1058.
58. Levy, R., Tourani, J.M., Jais, J.P., Andrieu, J.M., 1994. CD4 cell count of asymptomatic patients remains stable under cyclosporin A. Abstract PB0298: X International Conference on AIDS, Yokahama, Japan.
59. Manoff S.B., Farzadegan H., Munoz A., Astembroski J.A., Vlahov D., Rizzo R.T., Solomon L., Graham N.M. The effect of latent Mycobacterium tuberculosis infection on HIV disease progression and HIV RNA load among injecting drug users. J. Infect. Dis. 174:1996;299-308.
60. Margolick J.B., Munoz A., Vlahov D., Solomon L., Astomborski J., Cohn S., Nelson K.E. Changes in T-lymphocyte subsets in intravenous drug users with HIV-1 infection. J. Am. Med. Assoc. 267:1992;1631-1636.
61. Margolick J.B., Munoz A., Vlahov D., Astemborski J., Solomon L., He X.Y., Nelson K.E., Saah A.J. Direct comparison of the relationship between clinical outcome and change in CD4+ lymphocytes in human immunodeficiency virus-positive homosexual men and injecting drug users. Arch. Intern. Med. 154:1994;869-875.
62. Margolick J.B., Munoz A., Donneberg A.D., Park L.P., Galai N., Giorgi J.V. Failure of T-cell homeostasis preceding AIDS in HIV-1 infection. The multicenter AIDS cohort study. Nature Med. 1:1995;674-680.
63. Margolick J.B., Farzadegan H., Hoover D.R., Saah A.J. Relationship between infectious cell-associated human immunodeficiency virus type 1 load, T lymphocyte subsets, and stage of infection in homosexual men. J. Infect. Dis. 173:1996;468-471.
64. McDonough R.J., Madden J.J., Falek A., Shafer D.A., Pline M., Gordon D., Bokos P., Kuehnle J.C., Mendelson J. Alteration of T and null lymphocyte frequencies in the peripheral blood on human opiate addicts: in vivo evidence of opiate receptor sites on T lymphocytes. J. Immunol. 125:1980;2539-2543.
65. Meisheri K., Isom G.E. Influence of immune stimulation and suppression of on morphine physical dependence and tolerance. Res. Commun. Chem. Pathol. Pharmacol. 19:1978;85-99.
66. Mellors J.W., Rinaldo C.R. Jr., Gupta P., White R.M., Todd J.A., Kingsley L.A. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 272:1996;1167-1170.
67. Membrano L., Irony I., Dere W., Klein R., Bigliere E.G., Cobb E. Adrenocortical function in acquired immunodeficiency syndrome. J. Clin. Endocrinol. Metab. 65:1987;482-487.
68. Merenich J.A., McDermott M.T., Asp A.A., Harrison S.M., Kidd G.S. Evidence of endocrine involvement early in the course of human immunodeficiency virus infection. J. Clin. Endocrinol. Metab. 70:1990;566-571.
69. Meyaard L., Hovenkamp E., Keet I.P.M., Hooibrink B., de Jong I.H., Otto S.A., Miedema F. Single-cell analysis of IL-4 and IFN-γ production by T cells from HIV-infected individuals. J. Immunol. 157:1996;2712-2718.
70. Mientjes G.H., van Ameijden E.J., Goudsmit J., Miedema F., Coutinho R.A. Progression of HIV infection among injecting drug users: Indications for a lower rate of progression among those who have frequently borrowed injecting equipment. AIDS. 7:1993;1363-1370.
71. Molitor T.W., Morilla A., Risdhal J.M., Murtaugh M.P., Chao C.C., Peterson P.K. Chronic morphine administration impairs cell-mediated immune responses in swine. J. Pharmacol. Exp. Ther. 260:1992;581-586.
72. Montella F., DiSora F., Perucci C., Abeni D.D., Rechia O. T-lymphocyte subsets in intravenous drug users with HIV-1 infection [Letter]. J. Am. Med. Assoc. 268:1992;2516-2517.
73. Munoz A., Carey V., Saah A.J., Phair J.P., Kingsley L.A., Fahey J.L., Ginzburg H.M., Polk B.F. Predictors of decline in CD4 lymphocytes in a cohort of homosexual men infected with human immunodeficiency virus. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 1:1989;396-404.
74. Munoz A., Vlahov D., Solomon L., Margolick J.B., Bareta J.C., Cohn S., Astemborski J., Nelson K.E. Prognostic indicators for development of AIDS among intravenous drug users. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 5:1992;694-700.
75. Murphey-Corb M., Martin L.N., Davison-Fairburn B., Montelaro R.C., Miller M., West M., Ohkawa S., Baskin S.B., Zhang J.-Y., Putney S.C., Allison A.C., Eppstein D.A. A formalin-inactivated whole SIV vaccine confers protection in macaques. Science. 246:1989;1293-1297.
76. Nott K.H., Vedhara K., Spickett G.P. Psychology, immunology, and HIV. Psychoneuroendocrinology. 20:1995;451-474.
77. Nowak M.A., McMichael A.J. How HIV defeats the immune system. Sci. Am. 273:1995;58-65.
78. Panteleo G., Cohen O.J., Schwartzentruber D.J., Graziosi C., Vaccarezza M., Fauci A.S. Pathogenic insights from studies of lymphoid tissue from HIV-infected individuals. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 10:1995;S6-14.
79. Panteleo G., Demarest J.F., Schaker T., Vaccarezza M., Cohen O.J., Daucher M., Graziosi C., Schnittman S.S., Quinn T.C., Shaw G.M., Perrin L., Tambussi G., Lazzarin A., Sekaly R.P., Soudeyns H., Corey L., Fauci A.S. The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc. Natl. Acad. Sci. U.S.A. 94:1997;254-258.
80. Pelletier E., Wain-Hobson S. Research commentary: AIDS is not caused by the extreme genetic variability of HIV. J. NIH Res. 8:1996;45-49.
81. Peterson P.K., Sharp B., Gekker G., Brumitt C., Keane W.F. Opioid-mediated suppression of cultured peripheral blood mononuclear cell respiratory burst activity. J. Immunol. 138:1987;3907-3912.
82. Peterson P.K., Sharp B.M., Gekker G., Porteghese P.S., Sannerud K., Balfour H.H. Jr. Morphine promotes the growth of HIV-1 in human peripheral blood mononuclear cell cocultures. AIDS. 4:1990;869-873.
83. Peterson P.K., Gekker G., Chao C.C., Schut R., Molitor T.W., Balfour H.H. Jr. Cocaine potentiates HIV-1 replication in human peripheral blood mononuclear cell cocultures. J. Immunol. 146:1991;81-84.
84. Pezzotti P.A., Galai N., Munoz A., Vlahov D., Rezza G. Decremento dei linfociti CD4+ nell'infezione da HIV: uno studio longitudinale su 941 individui con data di sieroconversione nota. Articoli Originali. 5:1994;93-100.
85. Pezzotti P., Phillips A.N., Dorrucci M., Galai N., Vlahov D., Rezza G. HIV exposure category and age in the progression to AIDS in a longitudinal study of 1199 individuals with known seroconversion rates. Br. Med. J. 310:1996;941-944.
86. Plotnikoff, N.P., Faith, R.E., Murgo, A.J., Good, R.A., 1986. Enkephalins and Endorphins. Stress and the Immune Axis. Plenum Press, New York, N.Y.
87. Rabin R.L., Roderer M., Maldonado Y., Petru A., Hezenberg L.H., Herzenberg L.A. Altered representation of naive and memory CD8 T cell subsets in HIV-infected children. J. Clin. Invest. 95:1995;2054-2060.
88. Rezza G., Lazzarin A., Angarano G., Zerboni R., Sinicco A., Salassa B., Pristera R., Barbanera M., Ortana L., Aiuti F., Costigliola P., Gafa S., Tirreli U., Pezzotti P., Mennito-Ippolito P. Risk of AIDS in HIV seroconverters: A comparison between intravenous drug users and homosexual males. Eur. J. Epidemiol. 6:1990;99-101.
89. Risdhal J.M., Peterson P.K., Chao C.C., Pijoan C., Molitor T.W. Effects of morphine dependence on the pathogenesis of swine herpes virus infection. J. Infect. Dis. 167:1993;1281-1287.
90. Roederer M., Dubs J.G., Anderson M.T., Raju P.A., Herzenberg L.A., Herzenberg L.A. CD8 naive T cell counts decrease progressively in HIV-infected adults. J. Clin. Invest. 95:1995;2061-2066.
91. Rothenberg R., Woelfel M., Stoneburner R., Milbing J., Parker R., Truman B. Survival with the acquired immunodeficiency syndrome: experience with 5833 cases in New York City. New Engl. J. Med. 317:1986;1297-1302.
92. Saksela K., Stevens C., Rubinstein P., Baltimore D. Human immunodeficiency virus type 1 mRNA expression in peripheral blood cells predicts disease progression independently of the numbers of CD4+ lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 91:1994;1104-1108.
93. Samuels J., Vlahov D., Anthony J.C., Chaisson R.E. Measurement of risk behaviors among intravenous drug users. Br. J. Addiction. 87:1992;417-428.
94. Sapira J.D. The narcotic addict as a medical patient. Am. J. Med. 45:1968;555-588.
95. + memory T cells by human immunodeficiency virus type 1: Evidence for a role in the selective T-cell functional defects observed in infected individuals. Proc. Natl. Acad. Sci. U.S.A. 87:1990;6058-6062.
96. Selnes O.A., McArthur J.C., Royal W., Updike M.L., Nance-Sproson T., Concha M., Gordon B., Solomon L., Vlahov D. HIV-1 infection and intravenous drug use: longitudinal neurophysical evaluation of asymptomatic patients. Neurology. 42:1992;1924-1930.
97. Selwyn P.A., Alcabes P., Hartel D., Buono D., Schoenbaum E.E., Klein R.S., Darenny K., Friedland G.H. Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. New Engl. J. Med. 327:1992;1697-1703.
98. Shavit Y., Depaulis A., Martin F.C., Terman G.W., Pechnick R.N., Zane C.J., Gale R.P., Liebeskind J.C. Involvement of brain opiate receptors in the immune-suppressive effects of morphine. Proc. Natl. Acad. Sci. U.S.A. 83:1986;7114-7117.
99. Shavit Y., Terman G.W., Lewis J.W., Zane C.J., Gale R.P., Liebeskind J.C. Effects of footshock stress and morphine on natural killer lymphocytes in rats: studies of tolerance and cross tolerance. Brain Res. 372:1986;382-385.
100. Spijkerman I.J., Koot M., Keet I.P., van den Hoek A.J., Miedema F., Coutinho R.A. Lower prevalence and incidence of HIV-1 syncytium-inducing phenotype among injecting drug users compared with homosexual men. AIDS. 9:1995;1085-1092.
101. Spijkerman I.J., Langendam M.W., Veugelers P.J., van Ameijden E.J., Keet I.P., Geskus R.B., van den Hoek A.J., Coutinho R.A. Differences in progression to AIDS between injection drug users and homosexual men with documented dates of seroconversion. Epidemiology. 7:1996;571-577.
102. Tross S., Hirsch D.A. Psychological distress and neuropsychological complications of HIV infection and AIDS. Am. Psychologist. 43:1988;929-934.
103. Tubaro E., Borelli G., Croce C., Cavallo G., Santiangeli G. Effect of morphine on resistance to infection. J. Infect. Dis. 148:1983;656-666.
104. Tubaro E., Avico U., Santiangeli C., Zuccaro P., Cavallo G., Pacifica R., Croce C., Borelli G. Morphine and methadone, impact on human phagocytic physiology. Int. J. Immunopharmacol. 7:1985;865-874.
105. Veyries M.-L., Sinet M., Desforges B., Rouveix B. Effects of morphine on the pathogenesis of murine Friend retrovirus infection. J. Pharmacol. Exp. Ther. 272:1995;498-504.
106. Vlahov D., Anthony J.C., Munoz A., Margolick J., Nelson K.E., Ceelentano D.D., Solomon L., Polk B.F. The ALIVE Study: a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. NIDA Res. Monogr. Ser. 109:1991;75-100.
107. Vlahov, D., Munoz, A., Saah, A.J., Solomon, L., Palenecik, J., Margolick, J. B., Astembroski, J., Bareta, J., Nelson, K.E., 1992. Prognostic indicators for development of AIDS in two cohorts. Abstract: VIIIth International Conference on AIDS, Amsterdam, Netherlands.
108. Vlahov D., Hoover D.R., Astemborski J., Fuller, C., Graham, N.M.H., Margolick, J.B., 1996. Continuous vs. intermittent patterns of injection drug use, episodes of drug withdrawal or overdose do not predict HIV related immunosuppression in injection drug users. Abstract: XI International Conference on AIDS, Vancouver, Canada.
109. Westby M., Manca F., Dalgleish A.G. The role of host immune responses in determining the outcome of HIV infection. Immunol. Today. 17:1996;120-126.
110. Wolinsky S.M., Korber B.T.M., Neumann A.U., Daniels M., Kunstman K.J., Whetsell A.J., Furtado M.R., Cao Y., Ho D.D., Safrit J.T., Koup R.A. Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science. 272:1996;537-542.
111. Wybran J., Appelboom T., Famaey J.P., Govaerts A. Suggestive evidence for receptors for morphine and methionine-enkephalin on normal human blood T lymphocytes. J. Immunol. 123:1979;1068-1070.